NEO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
NeoGenomics Inc (NEO) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has positive developments such as the launch of RaDaR ST and a growing market opportunity, its financial performance shows declining net income, EPS, and gross margin, which are critical for long-term growth. Additionally, technical indicators and trading sentiment do not signal a strong entry point currently.
The MACD is negative and contracting, RSI is neutral at 40.995, and moving averages are converging, indicating no clear trend. The stock is trading below the pivot level of 10.435, with key support at 9.53 and resistance at 11.341.
Launch of RaDaR ST for molecular residual disease detection, targeting a $20 billion market with high sensitivity for early tumor DNA detection.
Declining net income (-35.52% YoY), EPS (-33.33% YoY), and gross margin (-2.43% YoY) in the latest quarter. Pre-market price down by -0.59%, indicating weak short-term sentiment.
In Q4 2025, revenue increased by 10.56% YoY to $190.17M. However, net income dropped to -$9.88M (-35.52% YoY), EPS fell to -0.08 (-33.33% YoY), and gross margin declined to 43.83% (-2.43% YoY).
Analysts have recently raised price targets, with Piper Sandler increasing it to $13 and TD Cowen to $16, both maintaining positive ratings. However, BofA remains Neutral, citing headwinds and a preference for companies with higher R&D exposure.
